Septic Shock Clinical Trial
Official title:
Red Blood Cell Transfusion Improves Perfusion Parameters in Septic Shock Patients With Hypoperfusion: a Prospective Randomized Study
The purpose of this study was to evaluate the immediate effects of red blood cells
transfusion on central venous oxygen saturation and lactate levels in septic shock patients
randomized to two different hemoglobin levels.
The influence of red blood cell (RBC) transfusion on the adequacy of oxygen delivery (DO2)
and supply (VO2) could be assessed by systemic oxygen variables such as central venous
oxygen saturation (ScvO2) and lactate levels. Although it is not clear that alterations in
these parameters actually represent an improvement in the DO2/VO2 ratio, they might
represent a better transfusion trigger than the absolute hemoglobin value.
Patients admitted with a diagnosis of septic shock and hemoglobin levels lower than 9.0 g/dL
, less than 48 hours of shock diagnosis, were included, a central venous catheter in the
superior vena cava and signed informed consent. The investigators randomized all patients
into two groups. Patients in the liberal group received transfusions immediately, as the
objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group,
transfusion was withheld until their hemoglobin levels fell below 7.0 g/dL.
Each time a patient received a transfusion, the investigators collected a set of laboratory
tests, including hemoglobin levels, ScvO2 and lactate, at two time points, immediately
before transfusion and one hour after its ending.
The sample size was calculated by considering that in 80% of the transfusions in patients in
the restrictive group ScvO2 would improve compared to only 45% of those in the liberal
group, with an alpha error of 0.05 and 80% power. Improvement was defined as an increase of
5% over the pre-transfusion ScvO2. Twenty-eight transfusions in each group would be
necessary, but to correct for potential non-parametric distribution of the main variables,
the number was adjusted to 35 transfusions in each group.
Trends in ScvO2 and lactate were categorized as worsening or improving. The investigators
defined improvement when ScvO2 reached 70% in patients with baseline levels below this
threshold or when there was an absolute increase of at least 5% after transfusion. Any
increase in patients with previous ScvO2 ≥ 70% was considered to be "no change". Worsening
was defined as a reduction of 5% in the previous levels or a decline to less than 70% in
patients with pre-transfusion levels in the range of 70 to 75%. The investigators also
carried out a ROC curve analysis to assess the accuracy of the pre-transfusion hemoglobin
levels, pre-transfusion lactate and pre-transfusion ScvO2 in predicting the patients whose
ScvO2 would increase more than 5% with transfusion. For this analysis, the investigators
used a different approach because it would also be necessary to analyze patients with a
lower chance of response to assess the prediction of response. Thus, this analysis included
all patients with ScvO2 below 75%, rather than only those below 70%. As before, the
investigators defined improvement as any increase ≥ 5%. The investigators did not consider
patients with levels above 75% in this analysis, as the physiological interpretation of this
situation is challenging. The investigators considered as altered any lactate levels above
1.5 times the reference level, and a change ≥ 10% was defined as improvement or worsening.
In patients with baseline normal levels, the status was recorded as worsening if a 10%
increase was detected. Afterwards, the investigators tested the association between these
categorized variables and the baseline levels of hemoglobin. The impact on perfusion was
also assessed by the determination of Δlactate (lactate post-transfusion x 100/lactate
pre-transfusion) and ΔScvO2 (ScvO2 post-transfusion x 100/ScvO2 pre-transfusion), and their
correlation with the baseline hemoglobin levels was analyzed using the Spearman correlation
test.
In all tests, the results were considered significant if the p level was lower than 0.05.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Completed |
NCT02204852 -
Co-administration of Iloprost and Eptifibatide in Septic Shock Patients
|
Phase 2 | |
Completed |
NCT02079402 -
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
|
Phase 4 |